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Ventricular Assist Devices (VADs) are commonly implanted to assist patients suffering from
heart diseases. They provide long- and short-term support for the human heart and help patients
to recover from heart attacks and from congestive heart failure. It is essential to design blood-
sensitive VADs to minimise the risk of hemolysis and thrombosis. The blood pump, however,
must operate at a wide range of flow rates and pressure heads which makes a low-risk design a
challenging task. In this study the flow in a centrifugal blood pump, provided by the U.S. Food
and Drug Administration (FDA), is investigated by means of numerical simulations on high
performance computers. The simulations are carried out for different operation REYNOLDS
numbers. A total of 15 pump revolutions is performed to obtain quasi-steady results. The pres-
sure drop across the pump is considered to study convergence of the solution and to characterise
the energy loss of the device. Investigations of the velocity field show that there exist high ve-
locities and strong velocity gradients and shear layers in the outflow region potentially leading
to hemolysis. Investigations of the wall-shear stress reveal the existence of thin boundary lay-
ers at the blade tips. Finally, the motor torque is investigated to identify the force acting on
the blades. All the findings show that there is a strong need to develop more blood-sensitive
designs to reduce the risk of hemolysis and thrombosis.
1 Introduction
In 2014, about 26 million people worldwide suffered from heart failure1, which is the most
common fatal disease in developed countries. Heart failure develops gradually as the heart
muscle weakens. It is caused by a dysfunction of the heart’s ventricle that limits the cardiac
performance and can often only be treated by heart transplant. However, only 5,000 donor
hearts become available each year, while 50,000 patients remain waiting2.
Ventricular Assist Devices (VADs) are the only viable bridging solution allowing pa-
tients to survive until a donor is found. Such devices consist of inflow and outflow cannulas
and a blood pump to support the ventricle pumping. The major advantage, e.g., over a Total
Artificial Heart (TAH), is that the native heart remains in the body while the VAD sustains
the natural blood flow by means of an external power supply. Two different major kinds
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of blood pumps exist, i.e., axial and centrifugal pumps. Axial blood pumps consist of a
rotor type impeller mounted in a small housing rotating at 8,000−15,000 rpm 3. Thereby,
the pump accelerates the blood in the streamwise direction based on the principle of the
Archimedean screw. High rotational speed may lead to non-physiological flow conditions,
i.e., high shear stress and the formation of recirculation zones. Such phenomena may in-
duce hemolysis and thrombosis. High shear rates may damage the red blood cells causing
excessive hemolysis which may lead to kidney and hence multiple organ dysfunction. The
formation of recirculation zones increases the likelihood of blood clots, which may circu-
late in the cardiovascular system and obstruct important arteries or veins. In contrast to
axial pumps, centrifugal pumps operate at a speed of 1,400 − 4,000 rpm and consist of a
non-occlusive pump head with several rotor blades mounted in a pump housing4. The fluid
enters through the head and is centrifugally accelerated by the perpendicularly mounted
pump head. The accelerated flow decelerates in the diverging outflow cannula causing a
pressure increase. As fluid is displaced at the discharge side of the pump, more fluid is
sucked in to replace it at the suction side leading to flow5.
Blood pumps must operate over a wide range of flow rates and pressure heads. Another
requirement is minimisation of the damage to blood cells. The intricacy of the problem
makes Computational Fluid Dynamics (CFD) a powerful tool for the analysis and design
of blood pumps. A review of the design and numerical analysis of both centrifugal and
axial blood pumps is given in Behbahani et al.6.
The investigations in this study concentrate on a centrifugal blood pump provided by
the U.S. Food and Drug Administration (FDA). The FDA aims at characterising the feasi-
bility of CFD methods for the design of medical devices. That is, they review the disad-
vantages and problems of medical devices and call health professionals’ attention to their
findings. At the end of 2013 the FDA invited academical as well as industrial organisations
of the CFD community to take part in a benchmark study that involves the analysis of the
flow in a typical blood pump. The study is composed of six test cases with different pump
speeds and REYNOLDS numbers in the range of Re = 210 · 103 to Re = 293 · 103. The
high REYNOLDS number regime requires large meshes to highly resolve the flow and High
Performance Computing (HPC) is mandatory to perform the simulations. They have been
carried out on the JUQUEEN7 system at the Ju¨lich Supercomputing Centre (JSC). Within
this work, the velocity field, secondary flow structures, the wall-shear stress, and the motor
torque are investigated to develop an understanding of the blood sensitivity of the FDA
blood pump. For validation of the numerical results the FDA has contracted 3 indepen-
dent laboratories to produce experimental data of the flow through the pump by means of
Particle Imaging Velocimetry (PIV).
This paper is organised as follows. The numerical method for the simulation of the
flow in the centrifugal FDA blood pump and the code scalability are described in Sec. 2.
Subsequently, the results of the simulations at several REYNOLDS numbers are presented
in Sec. 3. Finally, conclusions are drawn in Sec. 4.
2 Numerical Methods
In this section the numerical methods, i.e., the flow solver, the geometry of the problem and
the mesh generation as well as a scalability analysis of the simulation code are presented.
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2.1 Flow Solver
To simulate the flow in the FDA centrifugal blood pump a Finite Volume Method (FVM) is
used since it is well suited for CFD simulations of high REYNOLDS number flows in com-
plex geometries. In addition, FVM is known to demonstrate good parallel performance8.
Code Saturnea implements these advantages and is well suited for three-dimensional
calculations of steady or transient single-phase, incompressible or compressible, laminar
or turbulent flows9. Advanced and accurate turbulence modelling for Reynolds-Averaged
Navier-Stokes (RANS) and Large-Eddy Simulations (LES) represents a key feature of the
code. Its flow solver is based on a FVM, with a fully co-located arrangement for all vari-
ables and a predictor-corrector scheme for the time discretisation of the Navier-Stokes
equations. Parallelisation is handled using MPI, and some OpenMP pragmas are imple-
mented in version 3.2.x and 3.3.x of the code. Code Saturne is developed since 1997 at
EDF R&D and has found massive application for a variety of fluid mechanical problems
on several high-end machines10.
Within the framework of this study several RANS turbulence models were tested includ-
ing first order models such as k- and k-ω and, a Reynolds Stress Model (RSM), namely
the Rij-SSG (Speziale, Sarkar, Gatzki)11, 12. It was shown that the RSM represents an ap-
propriate choice with respect to modeling high-REYNOLDS number flow cases as isotropic
first order models (k-, k-ω) without rotation correction do not correctly model turbulence
effects with rotation, which induces anisotropy.
2.2 Geometry and Mesh Generation
a) b)
Figure 1. a) Picture of the FDA centrifugal blood pump, showing the long curved inlet, the pump and a part of
the long outlet; b) cross section of the pump including dimensions and interface (red line) between the rotor and
the housing which separates the rotating and static flow regions. All dimensions are given in mm.
The FDA centrifugal blood pump consists of two main components: the housing and
the rotor positioned inside it. The blood flows through a curved inlet tube into the housing
interior, where it meets a hub and then is rotated within the interior of the housing by means






Figure 2. Cross-sectional view (in purple) of a) static domain and b) dynamic domain meshes. At the interface
region pyramids can be seen.
For the grid generation SALOME version 6.6.0 b was used. To be able to simulate the
motion of the rotor, an interface is introduced and the mesh is split into two sub-meshes,
one for the rotor (which is moving) and one for the stator (which is static). The first sub-
mesh consists of the mesh of the rotor in a cylinder, and the second sub-mesh of the mesh
of the rest of the geometry minus the aforementioned cylinder (see the interface in Fig. 1 b).
An efficient and fully parallel mesh joining strategy is used at each time step between both
sub-meshes to create a full mesh used to solve the RANS equations. Hybrid meshes were
generated consisting of pyramids and tetrahedra, which had a defined number of regularly
arranged quadrangular surface elements at the interface. The corresponding sub-meshes
are shown in Fig. 2. The pump region, i.e., the first sub-mesh, was made of 14 million
cells at first and was later refined to 21 million cells for better resolution of critical areas.
The final full mesh including also the long inlet and outlet contained a total of 76 million
cells. The cell volume ranged between 5.05 · 10−15m3 and 9.14 · 10−12m3. The mesh was
designed fine enough to serve for the production runs of the FDA simulations, and scalable
wall-functions were used to better capture boundary layers. The same 76 million cell mesh
was used for all 6 simulations (see Tab. 1), which were conducted on the IBM Blue Gene/Q
JUQUEEN at Ju¨lich Supercomputing Centre13.
After computing the flows using the Code Saturne version 3.2.x, the flow structures
are visualised using ParaView14 version 3.14.1.
bhttp://www.salome-platform.org/
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2.3 Code Saturne Scalability Study
Code Saturne has demonstrated extreme scalability up to 1,572,864 MPI tasks, using 32
ranks per node on the IBM Blue Gene/Q Mira, Argonne National Laboratory. Fig. 3 shows
the speed-up of Code Saturne for three mesh sizes, consisting of 111 million, 889 mil-
lion, and 13 billion cells, respectively. The first two meshes (blue and green solid lines
respectively) have been run for the classical lid-driven cavity test case, using tetrahedral
cells. The third test (red solid line) is based on a mesh made of hexahedral cells and was
designed for LES in tube bundles.
A scalability study was also performed for this case and included test runs for all 6
cases which FDA asked for. Effects of partitioning algorithms on the scalability were also
investigated, using either serial METIS15 or PT-Scotch16. For a number of 1,024 - 65,536
processors METIS turned out to be the most efficient partitioner, requiring 11.7 seconds to
compute one iteration.
Figure 3. Speed-up of Code Saturne on Blue Gene/Qs, as a function of the number of MPI tasks. The blue
(111M cells) and green (889M cells) plots with respectively circle and triangle symbols are obtained on Blue
Joule (Hartree Centre, STFC, UK) and the red (13B cells) plot (square symbols) on Mira (DOE, Argonne, US).
3 Results of the Centrifugal Pump Analysis
Similar to the REYNOLDS number definition for stirred vessel flow, the FDA defined the
REYNOLDS number as Re = ρv2pid2/η, where ρ = 1035.0 kg/m3 is the blood den-
sity, v is the respective pump’s rotational speed, d = 0.052 m is the rotor diameter and
η = 0.0035 Pa is the blood viscosity. Blood is known to display non-Newtonian proper-
ties17. However, in experimental studies18 it has been shown that at shear rates γ˙ > 100
1
s , the viscosity of human blood with physiological hematocrit reaches a constant value,
thus justifying the choice of a Newtonian model at moderate and high shear rates. The
according flow conditions for all 6 cases are listed in Tab. 1. The data files which had to be
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Case volume flow rate [L/min] pump speed [rpm] REYNOLDS number
1 2.5 2500 293,073
2 2.5 3500 209,338
3 4.5 3500 293,073
4 6.0 2500 209,338
5 6.0 3500 293,073
6 7.0 3500 293,073
Table 1. Standard setup parameters of the blood pump benchmark as defined by the FDA.
Figure 4. Pressure evolution as a function of time for 15 revolutions for the example of simulation case 6. Pres-
sure values averaged over a full revolution are given in units of mmHg. The red curve represents zero-pressure
at the outlet and the green curve shows the pressure at the inlet.
submitted to the FDA included velocities and pressures in the blade passage plane and in
the outlet plane for all 6 simulation cases for prescribed rotor positions.
Depending on the flow case a fixed time step of 2.45 ·10−5s or 3.43 ·10−5s was applied
for typically 10,500 iterations in order to compute 15 revolutions of the rotor to approach
a quasi-stationary state which is shown in Fig. 4 for simulation case 6. The computational
effort (used CPU time) for computing one revolution of the blood pump while typically
using 32,768 MPI tasks for the 76 million cell mesh resulted in 11,279s or 3h 13min.
It can be observed that the solution converges towards a quasi-steady state and that the
averaged pressures over each revolution approach near-constant values, where a value of
80− 90mmHg corresponds to physiological pressure ranges.
Velocity and wall shear stress distributions for flow case number 5 are shown in Fig. 5.
The highest overall velocities are found in the narrow portion of the diffuser at the pump
outlet.
Fig. 6 shows the velocity field inside the blood pump housing. Inside the pump the
highest velocities occur behind the rotor blades. From the representation by means of ve-
locity vectors it can be observed that once the fluid has left the low-velocity inflow region,
fluid particles follow a circumferential path. Strong radial components are only visible
closely behind the rotor blades. Centrifugal forces pushing the particles to the outside are
adding an additional radial velocity component in the wake of the blades. The pressure
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Figure 5. Velocity distribution in the x,y-plane (left) and wall shear stress at the rotor surface (right) for simulation
case 5.
Figure 6. Velocity field inside the FDA blood pump housing (left) and velocity vector distribution at close prox-
imity to rotor surface (right) for simulation case 6. Rotor rotates in anti-clockwise direction.
loss caused by the velocity increase further accelerates particles in that region. The pres-
sure distribution (data not shown here) in the pump clearly shows low pressures behind
blade tips and high values in front of the tips and thereby confirms this interpretation. An-
other explanation for the elevated velocity values could be that there exist tip vortices in the
wake of the pump blades that rotate at high velocities, which add velocity behind the blade.
However, it is possible that RANS cannot capture these structures and LES computation and
analysis is necessary in the future studies.
Tab. 2 shows a summary of characteristic pressure, wall shear stress and torque values.
The given pressure head values represent the time-averaged pressure difference between
Case pressure head wall shear stress shaft torque
[103N/m2] [N/m2] [10−3 Nm]
1 77.6 61.2 8.4
2 49.3 27.4 13.3
3 38.6 135.5 18.8
4 -5.1 72.9 15.9
5 24.4 129.0 24.5
6 14.9 119.8 26.7
Table 2. Time-averaged pressure head (between inlet and outlet) over last rotation, time-averaged wall shear
stress magnitude over the housing rim and shaft torque for all 6 FDA simulation cases.
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the outlet and inlet. To that purpose pressure values were averaged over the inlet and
outlet areas respectively for a given rotor position. The time-averaged wall shear stress
magnitude was computed over the housing rim and was averaged over the last full rotation.
Finally, the torque values were computed from the velocity derivatives acting parallel to
the rotor surface and pressures perpendicular to the blades. According to the computed
values for the pressure head, simulation case 4 is not a feasible operating condition as a
very low and negative pressure would not support the required pumping function. All other
cases represent operating conditions, where the computed pressure heads lie in the range
of typical values reported in literature19. Values found for commercial blood pumps lie
typically in a range of 80 mmHg − 200 mmHg (10,666 − 26,666Pa) but can go up to
values of 700mmHg (93,331Pa) depending on the operating conditions. The computed
wall shear stress values are especially high for the simulation cases 3, 5 and 6. Values
between 119.8− 135.5Nm may cause hemolysis, especially because in centrifugal blood
pump the blood does not necessarily leave the pump after the first rotation. The blood
may rotate several times inside the housing, which strongly increases the shearing time for
blood cells and can cause strong deformation or rupture of these cells.
Post-processing and visualisation of the simulation data were performed on local com-
puters for distinct time steps and on JUVIS at the JSC if many time steps had to be loaded
simultaneously. Besides the various pictures requested by the FDA, it was possible to pro-
duce dynamic visualisation of the data including a movie of the blood flow situation inside
the FDA pump for the 76 million cell mesh. A snapshot from that movie is shown in Fig. 7.
About 1000 frames were generated through ParaView which amounts for over two and a
half revolutions. Pathline generation (not shown here) could also be performed.
Figure 7. Screenshot from a movie which was made for the 76 million mesh visualising the flow inside the FDA
blood pump. Colours represent the velocity magnitude. Rotor rotates in anti-clockwise direction.
4 Conclusion and Outlook
In this study the blood flow could be characterised for different operating conditions of
the FDA centrifugal blood pump. High shear stress regions could be identified both inside
the housing and in the diffusor region. The high shear values detected for some of the
flow cases may lead to hemolysis. The presented CFD study results can therefore serve
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to improve existing centrifugal blood pumps to obtain a hemocompatible design. The
required shaft torque, an important characteristic value for the operation of a centrifugal
blood pump, could equally be determined. All quantitative data and visualisations required
for the benchmark could be sent to the FDA. The performed flow field characterisation can
serve in the future to quantitatively estimate hemolysis using a mathematical model of red
blood cell deformation and damage. In the context of this study, Code Saturne could be
shown to be an efficient, scalable code which is suitable for the analysis of highly turbulent
rotating flows.
One important next step will be to compare the numerical results with real measure-
ments. Until now the FDA has not yet published any experimental results from the three
laboratories that were asked to perform comparative PIV studies but the publication of such
results is expected soon. From comparison to literature and from analytical considerations
it can already be concluded that the computed results are of the right order.
Another next step will be to perform Large-Eddy Simulations (LES) for the FDA blood
pump. LES computations will essentially help to understand the unsteady and highly dy-
namic flow in blood pumps and will support design studies for future VADs. The findings
will help to reduce the high shear stress in such devices and will hence minimise the risk
of hemolysis and thrombosis for the patient. These studies represent a step towards the
establishment of reliable methods to accurately predict blood flow and blood damage in
fast rotating biomedical devices. The LES computations will increase the computational
complexity and will at the same time require finer meshes of approximately 200 million
elements to capture turbulent effects, thus making the continued use of high performance
computing necessary.
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